2017
DOI: 10.1016/j.clml.2017.02.019
|View full text |Cite
|
Sign up to set email alerts
|

Minimal Residual Disease Assessment and Risk-based Therapy in Acute Lymphoblastic Leukemia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
20
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 21 publications
(22 citation statements)
references
References 39 publications
0
20
0
Order By: Relevance
“…MRD is increasingly being used in clinical practice as an independent prognostic marker for the duration of CR and long-term outcomes in patients with ALL, and for informing treatment decisions. 1922 The European Society for Medical Oncology (ESMO) and National Comprehensive Cancer Network clinical practice guidelines for adult patients with ALL recommend the quantification of MRD whenever possible, 6,23,24 but it is not yet clear whether MRD status alone is sufficient to predict prognosis, or whether it should be combined with other parameters, such as patient-related (e.g., age) or disease-related (e.g., cytogenetics) risk factors. In drug development, MRD response has been considered as an early marker of efficacy in clinical studies, with potential use as a surrogate endpoint in registration studies for accelerated drug approval.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…MRD is increasingly being used in clinical practice as an independent prognostic marker for the duration of CR and long-term outcomes in patients with ALL, and for informing treatment decisions. 1922 The European Society for Medical Oncology (ESMO) and National Comprehensive Cancer Network clinical practice guidelines for adult patients with ALL recommend the quantification of MRD whenever possible, 6,23,24 but it is not yet clear whether MRD status alone is sufficient to predict prognosis, or whether it should be combined with other parameters, such as patient-related (e.g., age) or disease-related (e.g., cytogenetics) risk factors. In drug development, MRD response has been considered as an early marker of efficacy in clinical studies, with potential use as a surrogate endpoint in registration studies for accelerated drug approval.…”
Section: Introductionmentioning
confidence: 99%
“…A large number of studies have shown that achievement of MRD-negative status correlates positively with CR duration, reduced risk of relapse, and HSCT success. 22,27 The use of MRD testing is individualized within a given study protocol, and hence there is wide variation in the test method used, the timing and sensitivity of MRD assessment, the characteristics of the patients, and the treatments used before and after MRD was assessed. We conducted a systematic review to capture the evidence supporting the clinical significance of MRD on clinical outcomes and used this evidence to inform a meta-analysis with the aim of quantifying the impact of MRD status on relapse-free survival (RFS) and overall survival (OS).…”
Section: Introductionmentioning
confidence: 99%
“…Advances in the field of subset recognition, risk stratification, chemotherapy, targeted therapy, and immunotherapy have led to significant therapeutic progress in adult acute lymphoblastic leukemia (ALL) over the past 20 years 1,2 . In the frontline setting, outcomes were improved by the use of pediatric-inspired chemotherapy 3,4 , minimal residual disease (MRD) to optimize risk classification and guide treatments 5,6 , targeted therapy in Philadelphia chromosome-positive (Ph+) ALL 7 , and monoclonal antibody therapy in B-precursor ALL (B-ALL) 8 . Pediatric-based chemotherapy together with the assessment of postinduction MRD has been used in Ph− ALL as a primary risk classifier and indicator for riskoriented allogeneic hematopoietic cell transplantation (HCT) [9][10][11][12][13][14] .…”
Section: Introductionmentioning
confidence: 99%
“…Testing for measurable ('minimal') residual disease (MRD) in people with acute leukaemias and other haematologic cancers has gained popularity [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16]. Results of these tests are now often included as an endpoint in reports of clinical trials outcomes and increasingly used in clinical practice with haematopoietic cell transplantation no exception.…”
Section: Introductionmentioning
confidence: 99%